VJHemOnc is committed to improving our service to you

ASH 2019 | Onvansertib with cytarabine or decitabine for R/R AML

VJHemOnc is committed to improving our service to you

Amer Zeidan

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the ongoing phase 1b dose-escalation trial (NCT03303339) evaluating the safety, efficacy and correlative analyses of onvansertib, a PLK-1 inhibitor, in combination with either low-dose cytarabine or decitabine in relapsed/refractory acute myeloid leukemia (AML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter